Which patient groups were sapropterin trials mainly centered on?

Sapropterin, also known as BJU 51, is an enzyme that works by reducing the levels of phenylalanine in the blood, which can be beneficial for individuals with phenylketonuria (PKU), a rare genetic disorder. Clinical trials involving sapropterin were primarily conducted among patients with PKU and certain variants of the condition, including those classified as mild, moderate, and in some cases, more severe [1]. These trials focused on assessing the drug's efficacy and safety as a potential treatment.

Studies specifically centered on sapropterin trials in pediatric and adult patients with PKU who were responding differently to dietary treatment, as those with mild PKU often have difficulty achieving sufficient reduction in phenylalanine levels through diet alone [2].

A trial conducted in patients with PKU and elevated dihydropteridine reductase (DHPR) activity found that sapropterin treatment significantly reduced blood phenylalanine levels, suggesting a potential therapeutic effect on DHPR-deficient patients [3].

These trial results indicated the potential for sapropterin to be an effective treatment for patients with PKU and other DHPR-related disorders.

Sources:

[1] https://www.drugpatentwatch.com/drug/Sapropterin
[2] https://pubmed.ncbi.nlm.nih.gov/19414736/
[3] https://pubmed.ncbi.nlm.nih.gov/16943447/